Improved drug therapy: Triangulating phenomics with genomics and metabolomics

Human Genomics

Volumn 8, Issue 1, 2014, Pages

  Monte, Andrew A ^a,b   Brocker, Chad ^c   Nebert, Daniel W ^d   Gonzalez, Frank J ^c   Thompson, David C ^a   Vasiliou, Vasilis ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^c EPN 3108   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Genomics; Individualized medicine; Metabolomics; Omics; Personalized medicine; Phenomics; Systems biology; Transcriptomics

Indexed keywords

BIOMICS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EPIGENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; METABOLOMICS; NONHUMAN; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; PHARMACOGENETICS; PHENOMICS; PREDICTIVE VALUE; PROTEOMICS; REVIEW; SYSTEMS BIOLOGY; TRANSCRIPTOMICS;

EID: 84946780102     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/s40246-014-0016-9     Document Type: Review

References (81)

1. Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C: Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 2006, 70:366-377.
2. Lee A, Ezzeldin H, Fourie J, Diasio R: Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol 2004, 2:527-532.
3. Gaughan EM, Costa DB: Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011, 3:113-125.
4. Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008, 19:717-723.
5. Monte AA, Heard KJ, Vasiliou V: Prediction of drug response and safety in clinical practice. J Med Toxicol 2012, 8:43-51.
6. Nebert DW, Zhang G, Vesell ES: From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008, 40:187-224.
7. Evans DA, Manley KA, Mc KV: Genetic control of isoniazid metabolism in man. Br Med J 1960, 2:485-491.
8. McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE: PharmGKB summary: very important pharmacogene information for N-Acetyltransferase 2. Pharmacogenet Genomics 2014, 24:409-425.
9. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116:2563-2570.
10. Burmester JK, Berg RL, Yale SH, Rottscheit CM, Glurich IE, Schmelzer JR, Caldwell MD: A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 2011, 13:509-518.
11. Caraco Y, Blotnick S, Muszkat M: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther 2008, 83:460-470.
12. Wang M, Lang X, Cui S, Fei K, Zou L, Cao J, Wang L, Zhang S, Wu X, Wang Y, Ji Q: Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: A randomized and controlled trial. Int J Med Sci 2012, 9:472-479.
13. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, et al: A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013, 369:2283-2293.
14. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M: A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013, 369:2294-2303.
15. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH: A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013, 369:2304-2312.
16. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT: Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
17. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, O'Connor GD, Chaila E, Alhusaini S, Shianna KV, Radtke RA, Heinzen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavalleri GL, Pirmohamed M: HLA-A 3101 and carbamazepineinduced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.
18. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP: Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005, 33:53-61.
19. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R, Pazdur R: Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007, 13:2318-2322.
20. Horwitz PA, Tsai EJ, Putt ME, Gilmore JM, Lepore JJ, Parmacek MS, Kao AC, Desai SS, Goldberg LR, Brozena SC, Jessup ML, Epstein JA, Cappola TP: Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation 2004, 110:3815-3821.
21. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Elashoff B, Baron H, Yee J, Valantine HA: Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010, 362:1890-1900.
22. Monte AA, Vasiliou V, Heard KJ: Omics screening for pharmaceutical efficacy and safety in clinical practice. J Pharmacogenomics Pharmacoproteomics 2012, S5.
23. Nebert DW, Jorge-Nebert L, Vesell ES: Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am J Pharmacogenomics 2003, 3:361-370.
24. A catalog of published genome wide association studies. [http://www. genome.gov/page.cfm?pageid=26525384&clearquery=1#result-Table]
25. Davis CE: The effect of regression to the mean in epidemiologic and clinical studies. Am J Epidemiol 1976, 104:493-498.
26. Wagner GP, Kenney-Hunt JP, Pavlicev M, Peck JR, Waxman D, Cheverud JM: Pleiotropic scaling of gene effects and the 'cost of complexity'. Nature 2008, 452:470-472.
27. Vandiedonck C, Beaurain G, Giraud M, Hue-Beauvais C, Eymard B, Tranchant C, Gajdos P, Dausset J, Garchon HJ: Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Natl Acad Sci U S A 2004, 101:15464-15469.
28. Li N, van der Sijde MR, Study LC, Bakker SJ, Dullaart RP, van der Harst P, Gansevoort RT, Elbers CC, Wijmenga C, Snieder H, Hofker MH, Fu J: Pleiotropic effects of lipid genes on plasma glucose, HbA1c and HOMA-IR levels. Diabetes 2014. Epub ahead of print.
29. Jones GL, Teng YS: A chemical and enzymological account of the multiple forms of human liver aldehyde dehydrogenase. Implications for ethnic differences in alcohol metabolism. Biochim Biophys Acta 1983, 745:162-174.
30. Newlin DB: The skin-flushing response: Autonomic, self-report, and conditioned responses to repeated administrations of alcohol in Asian men. J Abnorm Psychol 1989, 98:421-425.
31. Howard LA, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF: CYP2E1 1D regulatory polymorphism: Association with alcohol and nicotine dependence. Pharmacogenetics 2003, 13:321-328.
32. Tang K, Li X, Xing Q, Li W, Feng G, He L, Qin S: Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in Chinese Han populations from four different geographic areas of Mainland China. Genomics 2010, 95:224-229.
33. Brondani LA, Assmann TS, de Souza BM, Boucas AP, Canani LH, Crispim D: Meta-Analysis reveals the association of common variants in the uncoupling protein (UCP) 1-3 genes with body mass index variability. PLoS One 2014, 9:e96411.
34. Ehlers CL, Gizer IR: Evidence for a genetic component for substance dependence in Native Americans. Am J Psychiatry 2013, 170:154-164.
35. Carroll RJ, Bastarache L, Denny JC: R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics 2014, 30:2375-2376.
36. Neuraz A, Chouchana L, Malamut G, Le Beller C, Roche D, Beaune P, Degoulet P, Burgun A, Loriot MA, Avillach P: Phenome-wide association studies on a quantitative trait: Application to TPMT enzyme activity and thiopurine therapy in pharmacogenomics. PLoS Comput Biol 2013, 9:e1003405.
37. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, Pulley JM, Ramirez AH, Bowton E, Basford MA, Carrell DS, Peissig PL, Kho AN, Pacheco JA, Rasmussen LV, Crosslin DR, Crane PK, Pathak J, Bielinski SJ, Pendergrass SA, Xu H, Hindorff LA, Li R, Manolio TA, Chute CG, Chisholm RL, Larson EB, Jarvik GP, Brilliant MH, et al: Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol 2013, 31:1102-1110.
38. Langley RJ, Tsalik EL, van Velkinburgh JC, Glickman SW, Rice BJ, Wang C, Chen B, Carin L, Suarez A, Mohney RP, Freeman DH, Wang M, You J, Wulff J, Thompson JW, Moseley MA, Reisinger S, Edmonds BT, Grinnell B, Nelson DR, Dinwiddie DL, Miller NA, Saunders CJ, Soden SS, Rogers AJ, Gazourian L, Fredenburgh LE, Massaro AF, Baron RM, Choi AM, et al: An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med 2013, 5:95-113.
39. Bilder RM, Sabb FW, Cannon TD, London ED, Jentsch JD, Parker DS, Poldrack RA, Evans C, Freimer NB: Phenomics: The systematic study of phenotypes on a genome-wide scale. Neuroscience 2009, 164:30-42.
40. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
41. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Konsgen D, Dietel M, Fiehn O: Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006, 66:10795-10804.
42. Manna SK, Tanaka N, Krausz KW, Haznadar M, Xue X, Matsubara T, Bowman ED, Fearon ER, Harris CC, Shah YM, Gonzalez FJ: Biomarkers of coordinate metabolic reprogramming in colorectal tumors in mice and humans. Gastroenterology 2014, 146:1313-1324.
43. Mathe EA, Patterson AD, Haznadar M, Manna SK, Krausz KW, Bowman ED, Shields PG, Idle JR, Smith PB, Anami K, Kazandjian DG, Hatzakis E, Gonzalez FJ, Harris CC: Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res 2014, 74:3259-3270.
44. Widmann P, Reverter A, Fortes MR, Weikard R, Suhre K, Hammon H, Albrecht E, Kuehn C: A systems biology approach using metabolomic data reveals genes and pathways interacting to modulate divergent growth in cattle. BMC Genomics 2013, 14:798.
45. Rhee EP, Gerszten RE: Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012, 58:139-147.
46. Weiss RH, Kim K: Metabolomics in the study of kidney diseases. Nat Rev Nephrol 2012, 8:22-33.
47. Chen S, Kong H, Lu X, Li Y, Yin P, Zeng Z, Xu G: Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry. Anal Chem 2013, 85:8326-8333.
48. Kim JH, Yamaori S, Tanabe T, Johnson CH, Krausz KW, Kato S, Gonzalez FJ: Implication of intestinal VDR deficiency in inflammatory bowel disease. Biochim Biophys Acta 1830, 2013:2118-2128.
49. Veenstra TD: Metabolomics: The final frontier? Genome Med 2012, 4:40.
50. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996, 334:574-579.
51. Sirtori CR, Pasik C: Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994, 30:187-228.
52. Seidowsky A, Nseir S, Houdret N, Fourrier F: Metformin-Associated lactic acidosis: A prognostic and therapeutic study. Crit Care Med 2009, 37:2191-2196.
53. Johnson CH, Gonzalez FJ: Challenges and opportunities of metabolomics. J Cell Physiol 2012, 227:2975-2981.
54. Zheng Y, Yu B, Alexander D, Mosley TH, Heiss G, Nettleton JA, Boerwinkle E: Metabolomics and incident hypertension among blacks: The atherosclerosis risk in communities study. Hypertension 2013, 62:398-403.
55. Li F, Wang L, Guo GL, Ma X: Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos 2010, 38:871-878.
56. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE: Metabolite profiles and the risk of developing diabetes. Nat Med 2011, 17:448-453.
57. Ho JE, Larson MG, Vasan RS, Ghorbani A, Cheng S, Rhee EP, Florez JC, Clish CB, Gerszten RE, Wang TJ: Metabolite profiles during oral glucose challenge. Diabetes 2013, 62:2689-2698.
58. Bain JR, Muehlbauer MJ: Metabolomics reveals unexpected responses to oral glucose. Diabetes 2013, 62:2651-2653.
59. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ: Xenobiotic metabolomics: major impact on the metabolome. Annu Rev Pharmacol Toxicol 2012, 52:37-56.
60. Furie B: Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med 2013, 369:2345-2346.
61. Nebert DW: Extreme discordant phenotype methodology: An intuitive approach to clinical pharmacogenetics. Eur J Pharmacol 2000, 410:107-120.
62. Gu Q, Dillon CF, Burt VL: Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief 2010:1-8.
63. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA: Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 2002, 287:337-344.
64. Tinetti ME, Bogardus ST Jr, Agostini JV: Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004, 351:2870-2874.
65. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ: Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008, 52:818-827.
66. Monte AA, Heard KJ, Hoppe JA, Vasiliou V, Gonzalez FJ: The accuracy of self-reported drug ingestion histories in emergency department patients. J Clin Pharmacol 2014. Epub ahead of print.
67. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, Willer CJ, Jackson AU, Vedantam S, Raychaudhuri S, Ferreira T, Wood AR, Weyant RJ, Segre AV, Speliotes EK, Wheeler E, Soranzo N, Park JH, Yang J, Gudbjartsson D, Heard-Costa NL, Randall JC, Qi L, Vernon Smith A, Magi R, Pastinen T, Liang L, Heid IM, Luan J, Thorleifsson G, et al: Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010, 467:832-838.
68. Lander ES: Initial impact of the sequencing of the human genome. Nature 2011, 470:187-197.
69. Nebert DW, Zhang G, Vesell ES: Genetic risk prediction: individualized variability in susceptibility to toxicants. Annu Rev Pharmacol Toxicol 2013, 53:355-375.
70. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wagele B, Altmaier E, Deloukas P, Erdmann J, Grundberg E, Hammond CJ, de Angelis MH, Kastenmuller G, Kottgen A, Kronenberg F, Mangino M, Meisinger C, Meitinger T, Mewes HW, Milburn MV, Prehn C, Raffler J, Ried JS, Romisch-Margl W, Samani NJ, Small KS, Wichmann HE, Zhai G, Illig T, Spector TD, et al: Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011, 477:54-60.
71. Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, Prehn C, Altmaier E, Kastenmuller G, Kato BS, Mewes HW, Meitinger T, de Angelis MH, Kronenberg F, Soranzo N, Wichmann HE, Spector TD, Adamski J, Suhre K: A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010, 42:137-141.
72. Roede JR, Uppal K, Park Y, Lee K, Tran V, Walker D, Strobel FH, Rhodes SL, Ritz B, Jones DP: Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: A pilot study. PLoS One 2013, 8:e77629.
73. Jun HJ, Lee JH, Kim J, Jia Y, Kim KH, Hwang KY, Yun EJ, Do KR, Lee SJ: Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res 2014, 55:1098-1110.
74. Morvan D, Demidem A: Metabolomics and transcriptomics demonstrate severe oxidative stress in both localized chemotherapy-Treated and bystander tumors. Biochim Biophys Acta 1840, 2014:1092-1104.
75. Mukherjee K, Edgett BA, Burrows HW, Castro C, Griffin JL, Schwertani AG, Gurd BJ, Funk CD: Whole blood transcriptomics and urinary metabolomics to define adaptive biochemical pathways of highintensity exercise in 50-60 year old masters athletes. PLoS One 2014, 9:e92031.
76. Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, Hanna N, Alexander HR, Hussain SP: Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res 2013, 19:4983-4993.
77. Zhang Y, Deng Y, Zhao Y, Ren H: Using combined bio-omics methods to evaluate the complicated toxic effects of mixed chemical wastewater and its treated effluent. J Hazard Mater 2014, 272:52-58.
78. Xing EP, Curtis RE, Schoenherr G, Lee S, Yin J, Puniyani K, Wu W, Kinnaird P: GWAS in a box: statistical and visual analytics of structured associations via GenAMap. PLoS One 2014, 9:e97524.
79. Jannetto PJ, Bratanow NC: Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics 2009, 10:1157-1167.
80. Lotsch J, Skarke C, Liefhold J, Geisslinger G: Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004, 43:983-1013.
81. Boswell MV, Stauble ME, Loyd GE, Langman L, Ramey-Hartung B, Baumgartner RN, Tucker WW, Jortani SA: The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone. Pain Physician 2013, 16:E227-E235.